BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25161268)

  • 1. How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
    Kater AP; Tonino SH; Egle A; Ramsay AG
    Blood; 2014 Oct; 124(14):2184-9. PubMed ID: 25161268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
    Browning RL; Byrd WH; Gupta N; Jones J; Mo X; Hertlein E; Yu L; Muthusamy N; Byrd JC
    Cancer Immunol Res; 2016 Aug; 4(8):698-707. PubMed ID: 27287425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Itchaki G; Brown JR
    Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.
    Ramsay AG; Evans R; Kiaii S; Svensson L; Hogg N; Gribben JG
    Blood; 2013 Apr; 121(14):2704-14. PubMed ID: 23325833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide and chronic lymphocytic leukemia.
    González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
    Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
    Herman SE; Lapalombella R; Gordon AL; Ramanunni A; Blum KA; Jones J; Zhang X; Lannutti BJ; Puri KD; Muthusamy N; Byrd JC; Johnson AJ
    Blood; 2011 Apr; 117(16):4323-7. PubMed ID: 21378270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
    Fiorcari S; Martinelli S; Bulgarelli J; Audrito V; Zucchini P; Colaci E; Potenza L; Narni F; Luppi M; Deaglio S; Marasca R; Maffei R
    Haematologica; 2015 Feb; 100(2):253-62. PubMed ID: 25398834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
    Ramsay AG; Clear AJ; Fatah R; Gribben JG
    Blood; 2012 Aug; 120(7):1412-21. PubMed ID: 22547582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
    Han TT; Fan L; Li JY; Xu W
    Cancer Biol Ther; 2014 Jan; 15(1):3-9. PubMed ID: 24149438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
    Chen CI
    Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
    Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
    Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
    Chen CI; Bergsagel PL; Paul H; Xu W; Lau A; Dave N; Kukreti V; Wei E; Leung-Hagesteijn C; Li ZH; Brandwein J; Pantoja M; Johnston J; Gibson S; Hernandez T; Spaner D; Trudel S
    J Clin Oncol; 2011 Mar; 29(9):1175-81. PubMed ID: 21189385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
    Ramsay AG; Johnson AJ; Lee AM; Gorgün G; Le Dieu R; Blum W; Byrd JC; Gribben JG
    J Clin Invest; 2008 Jul; 118(7):2427-37. PubMed ID: 18551193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
    Maffei R; Fiorcari S; Martinelli S; Benatti S; Bulgarelli J; Rizzotto L; Debbia G; Santachiara R; Rigolin GM; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
    Leuk Lymphoma; 2018 Feb; 59(2):423-433. PubMed ID: 28639485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt TD; Ramsay AG; Zent CS; Leis JF; Tun HW; Call TG; LaPlant B; Bowen D; Pettinger A; Jelinek DF; Hanson CA; Kay NE
    Blood; 2013 May; 121(20):4137-41. PubMed ID: 23493782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
    Molica S
    Leuk Lymphoma; 2007 May; 48(5):866-9. PubMed ID: 17487728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
    Gassner FJ; Zaborsky N; Neureiter D; Huemer M; Melchardt T; Egle A; Rebhandl S; Catakovic K; Hartmann TN; Greil R; Geisberger R
    Haematologica; 2014 May; 99(5):67-9. PubMed ID: 24561794
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
    Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
    Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.